Skip to content
Farydak(panobinostat)
Farydak (panobinostat) is a small molecule pharmaceutical. Panobinostat was first approved as Farydak on 2015-02-23. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target histone deacetylase 1, histone deacetylase 8, histone deacetylase 2, histone deacetylase 4, histone deacetylase 9, histone deacetylase 6, histone deacetylase 3, and histone deacetylase 7.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Panobinostat lactate
Tradename
Company
Number
Date
Products
FARYDAKSecura BioN-205353 DISCN2015-02-23
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
farydakNew Drug Application2021-07-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myelomaD009101C90.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Panobinostat Lactate, Farydak, Secura
88838422028-06-13U-1669
79894942028-01-17DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XH: Histone deacetylase (hdac) inhibitors
L01XH03: Panobinostat
HCPCS
No data
Clinical
Clinical Trials
146 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.01051113
Primary myelofibrosisD055728D47.44316
Graft vs host diseaseD006086D89.811314
Polycythemia veraD011087D4511
ThalassemiaD013789EFO_1001996D5611
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.015171329
Myelodysplastic syndromesD009190D4676111
Hodgkin diseaseD006689C816419
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50759
Non-hodgkin lymphomaD008228C85.9426
Large b-cell lymphoma diffuseD016403C83.3166
Prostatic neoplasmsD011471C61425
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0335
GliomaD005910EFO_0000520335
LymphomaD008223C85.9345
MelanomaD008545414
Diffuse intrinsic pontine gliomaD000080443324
LeukemiaD007938C95234
Show 32 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801212
Non-small-cell lung carcinomaD00228966
Liver neoplasmsD008113EFO_1001513C22.022
Head and neck neoplasmsD00625822
Lung neoplasmsD008175C34.9022
Brain neoplasmsD001932EFO_0003833C7122
Castration-resistant prostatic neoplasmsD06412911
AnemiaD000740EFO_0004272D64.911
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.211
ThrombocytosisD013922D75.8311
Show 13 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePANOBINOSTAT
INNpanobinostat
Description
Panobinostat is a hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an antineoplastic agent and an angiogenesis modulating agent. It is a hydroxamic acid, a member of cinnamamides, a secondary amino compound and a methylindole. It is a conjugate base of a panobinostat(1+).
Classification
Small molecule
Drug classenzyme inhibitors: histone deacetylase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1
Identifiers
PDB5EF8
CAS-ID404950-80-7
RxCUI1603350
ChEMBL IDCHEMBL483254
ChEBI ID85990
PubChem CID6918837
DrugBankDB06603
UNII ID9647FM7Y3Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HDAC1
HDAC1
HDAC8
HDAC8
HDAC2
HDAC2
HDAC4
HDAC4
HDAC9
HDAC9
HDAC6
HDAC6
HDAC3
HDAC3
HDAC7
HDAC7
Organism
Homo sapiens
Gene name
HDAC1
Gene synonyms
RPD3L1
NCBI Gene ID
Protein name
histone deacetylase 1
Protein synonyms
Protein deacetylase HDAC1, Protein decrotonylase HDAC1, reduced potassium dependency, yeast homolog-like 1
Uniprot ID
Mouse ortholog
Hdac1 (433759)
histone deacetylase 1 (P97476)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,089 documents
View more details
Safety
Black-box Warning
Black-box warning for: Farydak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,994 adverse events reported
View more details